Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis

The prognostic value of tumor protein P53 (TP53) mutation for tyrosine kinase inhibitor (TKI) treatment in EGFR-mutant non-small-cell lung cancer (NSCLC) remains controversial. Therefore, the present meta-analysis was performed to investigate the potential association between the prognosis of TKI tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Bo, Zhao, Na, Du, Kang, Leng, Baolang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494618/
https://www.ncbi.nlm.nih.gov/pubmed/36238360
http://dx.doi.org/10.3892/ol.2022.13504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494618/
https://www.ncbi.nlm.nih.gov/pubmed/36238360
http://dx.doi.org/10.3892/ol.2022.13504

Ejemplares similares